CBD's seizure benefit may come from boosting clobazam levels, not direct anti-seizure effects
Clinical trial simulations suggest CBD's reduction of seizures in Lennox-Gastaut syndrome could be explained by its drug interaction with clobazam, which raises levels of clobazam's active metabolite 2- to 7-fold.
Quick Facts
What This Study Found
Simulations showed that the observed seizure reduction from CBD could be replicated by assuming: (1) patients on clobazam had a 2- to 7-fold increase in norclobazam (active metabolite) exposure, and (2) patients not on clobazam had seizure reduction and variability similar to placebo. This suggests CBD's apparent anti-seizure effect may be primarily a drug interaction rather than a direct pharmacological effect.
Key Numbers
CBD dose: 20 mg/kg/day. Norclobazam exposure increase: 2- to 7-fold. Simulated patients on 10 or 20 mg clobazam.
How They Did This
Clinical trial simulations modeling the effect of 20 mg/kg/day CBD on drop-seizure frequency in Lennox-Gastaut syndrome, assuming known CBD-clobazam interaction parameters.
Why This Research Matters
If CBD's benefit is primarily through boosting clobazam, simply increasing clobazam doses might achieve the same effect at lower cost, though with potentially more side effects.
The Bigger Picture
This challenges the narrative that CBD has independent anti-seizure properties and has implications for the FDA registration of Epidiolex and for patients and families investing in CBD treatment.
What This Study Doesn't Tell Us
Simulation study, not empirical trial. Assumptions may not fully reflect clinical reality. Does not account for all possible mechanisms of CBD action.
Questions This Raises
- ?If the benefit is from drug interaction, should clobazam doses be increased instead?
- ?Does CBD have any direct anti-seizure effects independent of drug interactions?
Trust & Context
- Key Stat:
- CBD raises clobazam's active metabolite 2-7 fold
- Evidence Grade:
- Simulation study based on known pharmacokinetic data, providing a plausible hypothesis but not proof.
- Study Age:
- 2020 simulation study.
- Original Title:
- Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
- Published In:
- British journal of clinical pharmacology, 86(2), 380-385 (2020)
- Authors:
- Bergmann, Kirsten Riber, Broekhuizen, Karen, Groeneveld, Geert Jan(2)
- Database ID:
- RTHC-02417
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Does CBD directly stop seizures?
This simulation study suggests CBD's seizure benefit may come from raising levels of clobazam's active metabolite rather than from direct anti-seizure effects, though other studies provide some evidence of independent action.
How does CBD interact with clobazam?
CBD increases levels of norclobazam (clobazam's active metabolite) 2- to 7-fold, which could account for the observed seizure reduction in patients taking both drugs.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02417APA
Bergmann, Kirsten Riber; Broekhuizen, Karen; Groeneveld, Geert Jan. (2020). Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.. British journal of clinical pharmacology, 86(2), 380-385. https://doi.org/10.1111/bcp.14158
MLA
Bergmann, Kirsten Riber, et al. "Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.." British journal of clinical pharmacology, 2020. https://doi.org/10.1111/bcp.14158
RethinkTHC
RethinkTHC Research Database. "Clinical trial simulations of the interaction between cannab..." RTHC-02417. Retrieved from https://rethinkthc.com/research/bergmann-2020-clinical-trial-simulations-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.